ArticleCellular and molecular life sciences : CMLS2026
Heparan sulfate as an attachment factor for ASFV is restricted by host HB-EGF.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
African swine fever virus (ASFV) is a highly virulent pathogen that poses a significant threat to the global pig industry, and no vaccines or effective treatments are currently available. Cellular attachment is initial and crucial for viral entry and subsequent infection. Understanding the molecular mechanisms of ASFV entry is therefore essential for developing antiviral strategies. Here, we show that cellular heparan sulfate (HS) assists ASFV attachment and subsequent entry into the target cell. Chemical inhibitors of HS and competition assays using heparin and heparan sulfate impair ASFV attachment and infection in the cultured cells. The direct binding between the ASFV virion and heparin is demonstrated by using heparin-coated beads, and this interaction can be blocked by free heparin. In addition, we identify host HB-EGF as a restriction factor against ASFV and reveal that the heparin-binding domain (HBD) is critical for its antiviral activity. The HBD-derived peptide exhibits strong binding affinity for heparin and exerts potent antiviral activity against ASFV. Together, our findings indicate that HS acts as an attachment factor for ASFV, and pharmacologically targeting it may represent a potential strategy for antiviral development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.